Lupin enters strategic collaboration with TB Alliance

02 Feb 2026 Evaluate

Lupin has entered into strategic collaboration with TB Alliance, a non-profit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly known as Q203), for the treatment of multiple mycobacterial diseases including tuberculosis (TB), leprosy, and buruli ulcer. 

Under the terms of the agreement, Lupin and TB Alliance will collaborate to support the clinical development and commercialization of Telacebec, to provide advanced treatment options for patients affected by these diseases. TB Alliance will continue to lead the development process, while Lupin will provide its expertise in global manufacturing, regulatory affairs, and supply chain to ensure global access to Telacebec.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

2340.75 39.05 (1.70%)
10-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1813.00
Dr. Reddys Lab 1313.90
Cipla 1333.10
Zydus Lifesciences 922.90
Lupin 2340.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×